Is the cost of the drug expensive?
advertisement

Here is the some steps to help you to save money on Shantinib purchase.


Read drug prescription

It is very important to know about what medicine is given by the doctor, for what condition, and when it needs to be taken in what dose. This information given by the doctor is called Prescription. The patients should be familiar with the medicine prescription, and the details about the medicine before purchasing it and using it. Some medications need not be prescribed by healthcare practitioners and can be purchased and used without prescription by the patients; these are called over-the-counter medications. Read the drug prescription information of Shantinib before taking it.

What is Shantinib

Shantinib interferes with the growth of some cancer cells.
Shantinib is used to treat certain types of leukemia, bone marrow disorders, and skin cancer, or certain tumors of the stomach and digestive system.
Shantinib may also be used for purposes not listed in Shantinib guide.

Shantinib side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
See also: Side effects (in more detail)
advertisement

Shantinib dosing

Usual Adult Dose for Chronic Myelogenous Leukemia:

Chronic phase: 400 mg orally once a day.
Accelerated phase: 600 mg orally once a day.
Disease progression chronic phase: 600 mg orally once a day.
Disease progression accelerated phase: 400 mg orally twice a day.
A dose increase from 400 mg to 600 mg in adult patients with chronic phase disease, or from 600 mg to 800 mg in adult patients in accelerated phase or blast crisis may be considered in the absence of severe adverse drug reaction and severe non-leukemia related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time), failure to achieve a satisfactory hematologic response after at least three months of treatment, failure to achieve a cytogenetic response after six to twelve months of treatment, or loss of a previously achieved hematologic or cytogenetic response.
Dose adjustments for Chronic Phase CML (starting dose 400 mg)
ANC less than 1.0 x 10(9)/L and/or Platelets less than 50 x 10(9)/L:
1. Stop Shantinib until ANC greater than or equal to 1.5 x 10(9)/L and platelets greater than or equal to 75 x 10(9)/L.
2. Resume treatment with Shantinib at the original starting dose of 400 mg or 600 mg.
3. If recurrence of ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L, repeat step 1 and resume Shantinib at a reduced dose (300 mg if starting dose was 400 mg, 400 mg if starting dose was 600 mg).
Dose adjustments for Ph+ CML: Accelerated Phase and Blast Crisis (starting dose 600 mg)
ANC less than 0.5 x 10(9)/L and/or Platelets less than 10 x 10(9)/L:
1. Check if cytopenia is related to leukemia (marrow aspirate or biopsy).
2. If cytopenia is unrelated to leukemia, reduce dose of Shantinib to 400 mg.
3. If cytopenia persists 2 weeks, reduce further to 300 mg.
4. If cytopenia persists 4 weeks and is still unrelated to leukemia, stop Shantinib until ANC greater than or equal to 1 x 10(9)/L and platelets greater than or equal to 20 x 109/L and then resume treatment at 300 mg.

Usual Adult Dose for Gastrointestinal Stromal Tumor:

For adult patients with unresectable and/or metastatic, malignant GIST:
Recommended dose: 400 mg/day
A dose increase up to 800 mg daily (given as 400 mg twice daily) may be considered, as clinically indicated, in patients showing clear signs or symptoms of disease progression at a lower dose and in the absence of severe adverse drug reactions.
For the adjuvant treatment of adult patients following complete gross resection of GIST:
Recommended dose: 400 mg/day
In the clinical study, Shantinib was administered for one year. The optimal treatment duration with Shantinib is not known.
Dose adjustments for GIST (starting dose 400 mg)
ANC less than 1.0 x 10(9)/L and/or Platelets less than 50 x 10(9)/L:
1. Stop Shantinib until ANC greater than or equal to 1.5 x 10(9)/L and platelets greater than or equal to 75 x 10(9)/L.
2. Resume treatment with Shantinib at the original starting dose of 400 mg.
3. If recurrence of ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L, repeat step 1 and resume Shantinib at a reduced dose of 300 mg.

Usual Adult Dose for Acute Lymphoblastic Leukemia:

For use in the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia :
Recommended dose: 600 mg/day for adult patients with relapsed/refractory Ph+ ALL
Dose adjustments for ALL (starting dose 600 mg)
ANC less than 0.5 x 10(9)/L and/or Platelets less than 10 x 10(9)/L:
1. Check if cytopenia is related to leukemia (marrow aspirate or biopsy).
2. If cytopenia is unrelated to leukemia, reduce dose of Shantinib to 400 mg.
3. If cytopenia persists 2 weeks, reduce further to 300 mg.
4. If cytopenia persists 4 weeks and is still unrelated to leukemia, stop Shantinib until ANC greater than or equal to 1 x 10(9)/L and platelets greater than or equal to 20 x 109/L and then resume treatment at 300 mg.

Usual Adult Dose for Systemic Mastocytosis:

Recommended dose: 400 mg/day for patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation. If c-Kit mutational status is not known or unavailable, treatment with Shantinib 400 mg/day may be considered for patients with ASM not responding satisfactorily to other therapies.
Dose adjustments for ASM (starting dose 400 mg)
ANC less than 1.0 x 10(9)/L and/or Platelets less than 50 x 10(9)/L:
1. Stop Shantinib until ANC greater than or equal to 1.5 x 10(9)/L and platelets greater than or equal to 75 x 10(9)/L.
2. Resume treatment with Shantinib at the original starting dose of 400 mg or 600 mg.
3. If recurrence of ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L, repeat step 1 and resume Shantinib at a reduced dose (300 mg if starting dose was 400 mg, 400 mg if starting dose was 600 mg).
For patients with ASM associated with eosinophilia (a clonal hematological disease related to the fusion kinase FIP1L1-PDGFRalpha):
Recommended starting dose: 100 mg/day
A dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy.
Dose adjustments for ASM associated with eosinophilia (starting dose 100 mg)
ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L:
1. Stop Shantinib until ANC greater than or equal to 1.5 x 10(9)/L and platelets greater than or equal to 75 x 10(9)/L.
2. Resume treatment with Shantinib at previous dose (i.e. before severe adverse reaction).

Usual Adult Dose for Hypereosinophilic Syndrome:

For patients with hypereosinophilic syndrome/chronic eosinophilic leukemia :
Recommended dose: 400 mg/day
Dose adjustments for HES/CEL (starting dose 400 mg)
ANC less than 1.0 x 10(9)/L and/or Platelets less than 50 x 10(9)/L:
1. Stop Shantinib until ANC greater than or equal to 1.5 x 10(9)/L and platelets greater than or equal to 75 x 10(9)/L.
2. Resume treatment with Shantinib at the original starting dose of 400 mg or 600 mg.
3. If recurrence of ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L, repeat step 1 and resume Shantinib at a reduced dose (300 mg if starting dose was 400 mg, 400 mg if starting dose was 600 mg).
For patients with HES/CEL patients with demonstrated FIP1L1-PDGFRalpha fusion kinase:
Recommended starting dose: 100 mg/day
Dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy.
Dose adjustments for HES/CEL with FIP1L1-PDGFRalpha fusion kinase (starting dose 100 mg)
ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L:
1. Stop Shantinib until ANC greater than or equal to 1.5 x 10(9)/L and platelets greater than or equal to 75 x 10(9)/L.
2. Resume treatment with Shantinib at previous dose (i.e. before severe adverse reaction).

Usual Adult Dose for Chronic Eosinophilic Leukemia:

For patients with hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL):
Recommended dose: 400 mg/day
Dose adjustments for HES/CEL (starting dose 400 mg)
ANC less than 1.0 x 10(9)/L and/or Platelets less than 50 x 10(9)/L:
1. Stop Shantinib until ANC greater than or equal to 1.5 x 10(9)/L and platelets greater than or equal to 75 x 10(9)/L.
2. Resume treatment with Shantinib at the original starting dose of 400 mg or 600 mg.
3. If recurrence of ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L, repeat step 1 and resume Shantinib at a reduced dose (300 mg if starting dose was 400 mg, 400 mg if starting dose was 600 mg).
For patients with HES/CEL patients with demonstrated FIP1L1-PDGFRalpha fusion kinase:
Recommended starting dose: 100 mg/day
Dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy.
Dose adjustments for HES/CEL with FIP1L1-PDGFRalpha fusion kinase (starting dose 100 mg)
ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L:
1. Stop Shantinib until ANC greater than or equal to 1.5 x 10(9)/L and platelets greater than or equal to 75 x 10(9)/L.
2. Resume treatment with Shantinib at previous dose (i.e. before severe adverse reaction).

Usual Adult Dose for Dermatofibrosarcoma Protuberans:

Recommended dose: 800 mg/day for patients with dermatofibrosarcoma protuberans
Dose adjustments for DFSP (starting dose 800 mg)
ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L:
1. Stop Shantinib until ANC greater than or equal to 1.5 X 10(9)/L and platelets greater than or equal to 75 x 10(9)/L.
2. Resume treatment with Shantinib at 600 mg.
3. In the event of recurrence of ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L, repeat step 1 and resume Shantinib at reduced dose of 400 mg.

Usual Adult Dose for Myeloproliferative Disorders:

Recommended dose: 400 mg/day for patients with myelodysplastic/myeloproliferative diseases (MDS/MPD)
MDS/MPD (starting dose 400 mg)
ANC less than 1.0 x 10(9)/L and/or Platelets less than 50 x 10(9)/L:
1. Stop Shantinib until ANC greater than or equal to 1.5 x 10(9)/L and platelets greater than or equal to 75 x 10(9)/L.
2. Resume treatment with Shantinib at the original starting dose of 400 mg or 600 mg.
3. If recurrence of ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L, repeat step 1 and resume Shantinib at a reduced dose (300 mg if starting dose was 400 mg, 400 mg if starting dose was 600 mg).

Usual Adult Dose for Myelodysplastic Diseases:

Recommended dose: 400 mg/day for patients with myelodysplastic/myeloproliferative diseases
MDS/MPD (starting dose 400 mg)
ANC less than 1.0 x 10(9)/L and/or Platelets less than 50 x 10(9)/L:
1. Stop Shantinib until ANC greater than or equal to 1.5 x 10(9)/L and platelets greater than or equal to 75 x 10(9)/L.
2. Resume treatment with Shantinib at the original starting dose of 400 mg or 600 mg.
3. If recurrence of ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L, repeat step 1 and resume Shantinib at a reduced dose (300 mg if starting dose was 400 mg, 400 mg if starting dose was 600 mg).

Usual Pediatric Dose for Chronic Myelogenous Leukemia:

Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase:
340 mg/m2 orally once a day or 170 mg/m2 orally twice a day
Maximum Dose: 600 mg daily
Duration of therapy: Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity.
Comments: There is no experience with Shantinib treatment in children under 1 year of age.
Dose adjustments for newly diagnosed pediatric chronic phase CML (starting dose 340 mg/m2):
ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L:
1. Stop Shantinib until ANC greater than or equal to 1.5 x 10(9)/L and platelets greater than or equal to 75 x 10(9)/L.
2. Resume treatment with Shantinib at previous dose (i.e. before severe adverse reaction).
3. In the event of recurrence of ANC less than 1.0 x 10(9)/L and/or platelets less than 50 x 10(9)/L, repeat step 1 and resume Shantinib at reduced dose of 260 mg/m2.

Usual Pediatric Dose for Acute Lymphoblastic Leukemia:

Newly diagnosed Ph+ ALL in combination with chemotherapy:
340 mg/m2 orally once a day
Maximum Dose: 600 mg once a day
Duration of therapy: Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity.
Comments: There is no experience with Shantinib treatment in children under 1 year of age.

Compare prices at online shops

Prices of the drug can vary in different shops. There will be a variation in price from pharmacy to an online shop. Most online shops will have a little lower price when compared to pharmacy stores, so you need to cross check before buying. Just go to a nearest pharmacy store and check for prices before you decide on buying. You should also be checking and comparing prices among various online stores and should be choosing the affordable and best store. The prices also vary based on brands, and you should note few stores sell specific brands, and you should learn to compare prices of same brand in different stores. Below are the prices of Shantinib medicine in some well-known online stores.

StrengthQuantityPrice, USDCountry
Shantha Biotechnics Pvt Ltd
100 mg10 Capsule$13.86India


Select the most affordable brand or generic drug

Generic drug is the basic drug with an active substance in it, and the name of the generic drug is same as active substance most of the times. Like Acetaminophen/Paracetemol is Generic name and it has different brand names like Tylenol, Acimol, Crocin, Calpol etc. All these Brand names contain the same Paracetemol, but the medications are manufactured by different companies, so the different brand names. Generic drug is always cheaper and affordable, and it can be replaced in place of brand name drug prescribed by the healthcare practitioner. The Generic medicine has same properties as branded medicine in terms of uses, indications, doses, side effects, so no need to worry on that. Just select the most affordable generic or branded medicine.

StrengthQuantityPrice, USDCountry
CELONIB film-coated tab 400 mg x 10's $44.80Celon (Vivilon)
CELONIB 100MG CAPSULE 1 strip(s) (10 capsules each) $12.60Celon Laboratories Ltd
100 mg60 $1.00Australia, Canada, NZ, Singapore, Turkey
100 mg120 $3.00Australia, Canada, Mauritius, NZ, Singapore, Turkey, UK, USA
100 mg120 $4.00Australia, Canada, India, Mauritius, NZ, Singapore, Turkey, UK, USA
100 mg120 $4.00Barbados, Canada, NZ, UK
400 mg30 $3.00Canada, Mauritius, Singapore, Turkey, UK, USA
400 mg30 $4.00Australia, Canada, India, Mauritius, NZ, Singapore, Turkey, UK
400 mg30 $3736.00
400 mg90 $10.00Barbados, Canada, NZ, UK
400 mg90 $10.00Australia, Canada, NZ, Singapore, Turkey
MITINAB 400MG TABLET 1 strip(s) (6 tablets each) $25.15Glenmark Pharmaceuticals Ltd
Mitinab 100mg Tablet $1.26Glenmark Pharmaceuticals Ltd
10 Tablets$4.21
advertisement

References

  1. "Imatinib". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
  2. "Imatinib". http://www.drugbank.ca/drugs/DB0061... (accessed August 28, 2018).
  3. "Bkj8m8g5hi: the unique ingredient identifier (unii) is an alphanumeric substance identifier from the joint fda/usp substance registration system (srs).". https://www.fda.gov/ForIndustry/Dat... (accessed August 28, 2018).

Shantinib - Frequently asked Questions

Can Shantinib be stopped immediately or do I have to stop the consumption gradually to ween off?

In some cases, it always advisable to stop the intake of some medicines gradually because of the rebound effect of the medicine.

It's wise to get in touch with your doctor as a professional advice is needed in this case regarding your health, medications and further recommendation to give you a stable health condition.

Who should not take Shantinib?

You should not use this medication if you are allergic to Shantinib.

To make sure Shantinib is safe for you, tell your doctor if you have:

FDA pregnancy category D. Do not use Shantinib if you are pregnant. It could harm the unborn baby. Use effective birth control, and tell your doctor if you become pregnant during treatment.

It is not known whether Shantinib passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine.

Do not give this medication to anyone under 1 year old without medical advice.

Shantinib can affect growth in children. Talk with your doctor if you think your child is not growing at a normal rate while using this medicine.

How should I take Shantinib?

Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended.

Take this medicine with a large glass of water.

You may dissolve the Shantinib tablet in water or apple juice to make swallowing easier.

Shantinib should be taken with a meal. Do not take Shantinib on an empty stomach.

Shantinib can lower blood cells that help your body fight infections and help your blood to clot. Your blood will need to be tested often. Your cancer treatments may be delayed based on the results of these tests.

Store at room temperature away from moisture and heat.

What other drugs will affect Shantinib?

Many drugs can interact with Shantinib. Not all possible interactions are listed here. Tell your doctor about all your medications and any you start or stop using during treatment with Shantinib, especially:

This list is not complete and many other drugs can interact with Shantinib. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Give a list of all your medicines to any healthcare provider who treats you.

Can Shantinib be taken or consumed while pregnant?

Please visit your doctor for a recommendation as such case requires special attention.

Can Shantinib be taken for nursing mothers or during breastfeeding?

Kindly explain your state and condition to your doctor and seek medical advice from an expert.

advertisement

Reviews

Following the study conducted by gmedication.com on Shantinib, the result is highlighted below. However, it must be clearly stated that the survey and result is based solely on the perception and impression of visitors and users of the website as well as consumers of Shantinib. We, therefore, urge readers not to base their medical judgment strictly on the result of this study but on test/diagnosis duly conducted by a certified medical practitioners or physician.

Patient reports

Patient reported useful

No survey data has been collected yet


Patient reported side effects

No survey data has been collected yet


Patient reported price estimates

No survey data has been collected yet


Patient reported frequency of use

No survey data has been collected yet


Patient reported doses

No survey data has been collected yet


Patient reported time for results

No survey data has been collected yet


Patient reported administration

No survey data has been collected yet


Patient reported age

No survey data has been collected yet


Patient reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 10 here

The information was verified by Dr. Vishal Pawar, MD Pharmacology